Skip to content
INCYIncyte

What Is INCY Fair Value?

Incyte (INCY) fair value estimate using multiple valuation models, updated daily.

As of August 29, 2026, Incyte (INCY) has a composite fair value estimate of $81.78 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $124.37, suggesting the stock is overvalued by 34.2%.

Data as of August 29, 2026 (today)

Composite Fair Value

Overvalued3 of 4 models

$81.78

vs. current price of $124.37(-34.2%)

Undervalued$81.78Overvalued
$124.37

How Is INCY Fair Value Calculated?

Four independent models estimate what INCY is worth. Each uses different inputs and assumptions. The composite blends them by weight.

INCY Intrinsic Value

Forward-looking models based on future cash flows

DCF (Discounted Cash Flow)

41% weight

Estimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →

$117.51

-5.5%

Fair Value

Inputs used

FCF: 1.2BGrowth: 5.0%Discount: 9%

DDM (Dividend Discount Model)

0% weight

If a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →

N/A

This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.

INCY Fair Value

Current fundamentals: earnings, assets, and growth rate

Graham Number (Value Investing)

29% weight

Created by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →

$49.71

-60.0%

Overvalued

Inputs used

EPS: $3.48Book Value: $31.57

PEG (Price/Earnings to Growth)

29% weight

Checks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.

$34.79

-72.0%

Overvalued

Inputs used

EPS: $3.48Growth: 5.0%

What If You Change the Assumptions?

Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.

Your DCF Fair Value

$117.51Fair Value

Current price $124.37 is 5.5% above this estimate

CheapFair ValueExpensive
5.0%
0.0%30.0%
8.7%
6.0%15.0%
2.5%
1.0%4.0%
15.0%
0.0%50.0%
View 10-year cash flow projections
YearProjected FCF (Free Cash Flow)Present Value
Year 1$1.24B$1.14B
Year 2$1.30B$1.10B
Year 3$1.37B$1.06B
Year 4$1.44B$1.03B
Year 5$1.51B$991.9M
Year 6$1.58B$958.0M
Year 7$1.66B$925.2M
Year 8$1.74B$893.5M
Year 9$1.83B$862.9M
Year 10$1.92B$833.4M
Terminal Value$31.68B$13.73B

What Are INCY's Key Financial Metrics?

Earnings & Growth

Current Price

$124.37

EPS (TTM)

$7.65

Forward P/E

13.9

Profit Margin

27.7%

Cash & Balance Sheet

Free Cash Flow

1.2B

EBITDA

1.9B

Book Value

$31.57

Total Debt

38.3M

What Do Analysts Say About INCY?

Low

$86.00

Average

$127.13

High

$155.00

Upside

+2.2%

Current $124.37Avg Target $127.13Buy24 analysts

INCY Fair Value FAQ

What is the fair value of INCY?

Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), INCY's estimated fair value is $81.78. The stock is currently trading at $124.37, which makes it overvalued by our analysis.

How is INCY's fair value calculated?

We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.

Is INCY overvalued or undervalued?

Based on our analysis, INCY is overvalued. The current price of $124.37 is 34.2% above our estimated fair value of $81.78.

What do Wall Street analysts say about INCY?

24 analysts cover Incyte with a consensus rating of "Buy." The average price target is $127.13, ranging from $86.00 to $155.00. This implies 2.2% upside from the current price.